Want to join the conversation?
$MYL 2Q15 Call: Our EpiPen continues to post strong results and maintains an 86% share in a multi-epinephrine market, and has delivered double-digit growth year-to-date. On the bottom line, our adjusted diluted earnings per share came in at $0.91 for the second quarter, up 32% compared to the same period last year, and exceeding our expectations.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.